Innovative approaches for cocaine pharmacotherapy using fMRI: The case of varenicline

Academical Medical Center0 个研究点目标入组 30 人开始时间: 2008年6月26日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1. Male, age 18-60 years;
•2. Current DSM-IV diagnosis of cocaine dependence, but recently detoxified and abstinent;
•3. Able to provide written informed consent and to comply with all study procedures
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Currently dependent on any substance other than cocaine or nicotine;
•2. History of depression that could be defined as even a single episode or recurrent episodes of depression, or depression necessitating hospitalization, or history of suicide attempt (see fotenote1);
•3. Severe neurological or psychiatric disorders (e.g., psychosis, bipolar illness, dementia, or any diseases that require psychotropic medications);
•4. Serious medical illnesses;
•5. Known hypersensitivity or allergy to varenicline, or receiving chronic therapy with medication that could interact adversely with one of the medications under study, within 30 days prior to randomization;
•6. Drugs known to influence binding to DA2 receptors, including neuroleptics, and methylphenidate;
•7. Received a drug with known potential for toxicity to a major organ system within the month prior to entering treatment;
•8. Clinically significant abnormal laboratory values, as measured by the treatment centre;
•9. Any disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication.
•10. Hypersensitivity to Jodium

发起方

Academical Medical Center